Zai Lab Limited

Hello, ladies and gentlemen. Thank you for standing by and welcome to ZayLab's first quarter 2024 financial results conference call. At this time, all participants are in listen-only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to Christine Chiao, Senior Vice President of Investor Relations. Please go ahead.

Thank you, operator. Good morning, good evening, and welcome to XyLab's first quarter 2024 earnings call. Today's call will be led by Dr. Samantha Du, XyLab's founder, CEO, and chairperson. She will be joined by Josh Smiley, President and Chief Operating Officer, Dr. Rafael Amato, President and Head of Global Oncology Research and Development, Dr. Harold Reinhart, President and Head of Global Development Neuroscience, Autoimmune, and Infectious Diseases, and Dr. Yaojin Chen, Chief Financial Officer. Jonathan Wang, Business Officer, will also be available to answer questions during the Q&A portion of the call. As a reminder, during today's call, we will be making certain forward-looking statements based on our current expectations. These statements are subject to numerous risks and uncertainties that may cause our actual results to differ materially from what we expect due to a variety of factors, including those discussed in our SEC filings. We will also refer to product revenue growth rates on a constant exchange rate basis, which is a non-GAAP financial measure. Please refer to our earnings release, Furnished with the SEC, on May 8, 2024, for additional information on this non-GAAP financial measure. At this time, it is my pleasure to turn the call over to Dr. Samantha Du.

Thank you, Christine, and good morning and good evening to all who are joining us today. I'm excited. to be here to share with you the results from our first quarter. But before I do so, I want to start with a few opening comments. We started Xilab with a vision to build a truly innovative and integrated biopharma company focused on bringing innovative medicines to address the unmet medical needs for patients in China and around the world. We have spent the past few years building our infrastructure, capabilities, and pipeline to get us where we are today. We're entering a period of robust growth driven by a late-stage pipeline of first and the best-in-class products. We're also advancing our global pipeline where we have three in the clinic today. And we expect to add new China, and global assets each year through both internal discovery and business development. This year, we expect three new product approvals, which follows the launch of VivGuard late last year. Over the next two to three years, we have the opportunity to launch multiple potential blockbuster products and many of those assets are expected to contribute significantly to our revenue way beyond 2028. As we scale our business, we'll continue to expand our operational efficiency and improve our productivity. Our first quarter results demonstrate our progress across each of these areas. Strong commercial execution increasing productivity, and pipeline progress. We expect 2024 to be a strong year for Xilat. We are on track to achieve the objectives outlined in our five-year strategic plan, including significant revenue growth and achieving profitability by the end of 2025. With a strong balance sheet, and a cash position of over 750 million USD, Cell Life is in a very good position. And with that, I'll pass the call to Josh. Josh?